Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Allogene Therapeutics reports for 2022

3/1/23 ALLO

Virgin Galactic reported for 2022

3/1/23 SPCE

HP's quarterly profit fell by 2.2 times

3/1/23 HPQ

First Solar ended 2022 with a loss of $44.166 million

3/1/23 FSLR

Thoma Bravo bought Coupa Software

2/28/23 COUP

The Big Lots announced a quarterly dividend

2/28/23 BIG

In year 2023, IPO can come as many companies as in 2021

2/28/23 MOEX

Sakhalin gas condensate processing plant project passes first stage of feasibility study

2/28/23 GAZP

eHealth reported for 2022

2/28/23 EHTH

VK NFT launches affiliate drops mechanics

2/28/23 VKCO